Uncomplicating the futureSM
 
Search

Healthcare Professionals

    Print page  

Adhesions and Radical Pelvic Surgery

Hysterectomy Photo
Seprafilm-treated pelvis at second look following radical oophorectomy12

Adhesions are a common consequence of pelvic surgery, forming after up to 95% of gynecologic laparotomies.1 Adhesions are the leading cause of small bowel obstruction following radical pelvic surgery2 and can complicate future surgeries, making it difficult to identify, reach, and separate tissues.3

Because they can obstruct areas of the abdominopelvic cavity, adhesions may limit future treatment options:

  • Added complexity in laparoscopy3
  • Limited distribution and effectiveness of intraperitoneal therapeutics3
  • Increased risk of postoperative radiation-induced small bowel perforation5

Additionally, they account for up to 48% of chronic pelvic pain cases6 and 75% of small bowel obstructions.7

SEPRAFILM® Adhesion Barrier is proven to help prevent postoperative adhesions.8 In recent studies, SEPRAFILM was shown to reduce adhesions observed at subsequent surgeries, resulting in:

  • Fewer inadvertent injuries9
  • Less operative time11
  • Reduced blood loss11

SEPRAFILM can be used to reduce adhesions following radical pelvic surgery.
1. DiZerega GS.  Peritoneal repair and postsurgical adhesion formation. In: Management of Common Problems in Obstetrics & Gynecology. Mishell DR, Goodwin Murphy T, Brenner PF, eds. Malden, MA: Blackwell Publishing; 2002: 267-271.
 
2. Stricker B, Blanco J, Fox H. The gynecologic contribution to intestinal obstruction in females. J Am Col Surg. 1999;178:617-620.
 
3. Nichols DH, Clarke-Pearson DL, eds. Gynecologic, Obstetric, and Related Surgery. 2nd ed. St. Louis, MO: Mosby, Inc; 1993.
 
3. Nichols DH, Clarke-Pearson DL, eds. Gynecologic, Obstetric, and Related Surgery. 2nd ed. St. Louis, MO: Mosby, Inc; 1993.
 
3. Nichols DH, Clarke-Pearson DL, eds. Gynecologic, Obstetric, and Related Surgery. 2nd ed. St. Louis, MO: Mosby, Inc; 1993.
 
5. Yamashita H, Nakagawa K, Tago M, et al. Small bowel perforation without tumor recurrence after radiotherapy for cervical carcinoma; report of seven cases. J Obstet Gynecol Res. 2006;32:235-242.
 
6. Stovall TG, Elder RF, Ling FW. Predictors of pelvic adhesions. J Reprod Med. 1989;34:345-348.
 
7. Scovill WA. Small bowel obstruction. In: Cameron JL, ed. Current Therapy in Surgery. St Louis, MO: Mosby Yearbook Medical Publishers, Inc; 1995:100-104.
 
8. SEPRAFILM Prescribing Information. Cambridge, MA: Genzyme Biosurgery; 2007
 
9. Tang C-L, Seow-Choen F, Fook-Chong S, Eu K-W. Bioresorbable adhesion barrier facilitates early closure of the defunctioning ileostomy after rectal excision. Dis Colon Rectum. 2003;46:1200-1207.
 
11. Fushiki H, Ikoma T, Kobayashi H, Yoshimoto H. Efficacy of SEPRAFILM as an Adhesion Barrier in Cesarean Sections. Obstetric and Gynecological Treatment [Japanese]. 2005;91(5):557-561.
 
11. Fushiki H, Ikoma T, Kobayashi H, Yoshimoto H. Efficacy of SEPRAFILM as an Adhesion Barrier in Cesarean Sections. Obstetric and Gynecological Treatment [Japanese]. 2005;91(5):557-561.
 
12. Bristow RE, Montz FJ. Prevention of adhesion formation after radical oophorectomy using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier. Gynecol Oncol. 2005;99:301-308.
 

 

SEPRAFILM Application in Gynecologic Procedures

Physician Testimonials

 

Indication

Seprafilm® Adhesion Barrier is indicated for the reduction of post-surgical adhesions in patients undergoing abdominal or pelvic laparotomy.

Important Safety Information

Seprafilm should not be wrapped around an intestinal anastomosis as such usage may result in increased anastomotic leak related events, such as abscess or peritonitis. The safety and effectiveness of Seprafilm has not been established in combination with other adhesion prevention products and/or in surgical procedures not within the abdominopelvic cavity. The safety and effectiveness of Seprafilm has also not been evaluated in cases of pregnancy, malignancy, or frank infection. The type and frequency of adverse events reported are consistent with events typically seen following abdominopelvic surgery when used as directed.

Please see full prescribing information.

Terms and Conditions of Use | Privacy Policy | Contact Us | This site is intended for United States residents only © 2002-2012 Genzyme Corporation. All rights reserved. Seprafilm and Genzyme are registered trademarks of Genzyme Corporation. genzyme logo